It looks like the Fed wonât completely
dominate this week!
This wasnât your normal do-nothing session ahead of a central bank
statement. The major indices soared on Tuesday by 1% or more based
on a trade Tweet from you-know-who.
President Trump wrote about a âvery goodâ phone conversion today
with China President Xi and that the two leaders would have an
âextended meetingâ at the G20 in Japan next week.
It would have been disheartening for these two guys to be in the
same place at the same time and NOT talk about the trade conflict
that has the whole world biting its fingernails.
Needless to say, the market loved the news. Nobody expects this
get-together to solve the problem, but weâll never get a trade
resolution unless these two sides get back to talking to each
other. There hasnât been much conversation since talks broke down
last month.
The reaction from the major indices on Tuesday was a broad rally,
especially for the trade-sensitive chip stocks that helped bring
about another solid performance from tech.
As a result, the NASDAQ continued to lead its counterparts with a
surge of 1.39% (or nearly 109 points) to 7953.88.
The Dow wasnât that far behind on a percentage basis as stocks
impacted by the trade conflict jumped on hopes that the G20 meeting
could set the stage for an agreement down the road.
The index rose 1.35% (or 353 points!) to 26,465.54.
However, the biggest news from the indices on Tuesday was from the
S&P. It finally broke through 2900 by rising 0.97% to
2917.75.
It is now less than 1% away from its all-time high!
So here we go. Tomorrowâs Fed statement will either keep this rally
going or stop it in its tracks.
The market isnât expecting action from the Fed tomorrow, but it
does want to hear dovish language that sets the stage for a cut (or
cuts) in the near future.
Letâs see if it gets what it wants...
Today's Portfolio Highlights:
Stocks Under $10: Now that the market is heading solidly
higher on expectations for an accommodative Fed, Brian thinks this
is a good time to buy the dip. That was the idea behind adding
Unisys (UIS), a worldwide technology services and solutions
company. The stock had a good session on Tuesday, but was right
around its 52-week low previously. The editor expects to capitalize
on further bounces moving forward. The portfolio is nearing its
goal of being fully invested. Todayâs addition of UIS brings it up
to 14 positions, which means thereâs only one open spot left. Read
the full write-up for more.
By the way, this portfolio easily had the best performer of the
session. SunPower (SPWR) was upgraded by a major brokerage today
along with a few other solar names. The stock soared by more than
22.5%. SPWR is now up nearly 33% in the portfolio since being added
in late April.
Value Investor: With the EU looking to stimulate,
the Fed about to cut rates and a Trump/Xi meeting coming to the
G20; Tracey thinks this is a good time to make a couple additions
to the portfolio. First up, the editor bought âboringâ office
products staple ACCO Brands (ACCO). But boring can be beautiful
when looking for value. This stock pays a dividend that yields 2.6%
and has a ârock solid managementâ to go along with its classic
value fundamentals. This Zacks Rank #2 (Buy) is a small cap so it
could be volatile, but itâs also expected to grow earnings by 11.5%
next year.
Meanwhile, it looks like WW (WW) made a mistake when it changed its
name from Weight Watchers. The company -- now focusing on wellness
instead of just weight loss -- gave back all of its Oprah gains,
but Tracey thinks the selloff was overdone. She still remembers
making more than 165% on âWTWâ in 2017. Despite bouncing off recent
lows, she still considers WW to be a value play and likes that
earnings are expected to jump next year by more than 23%. Read the
full write-up for more on todayâs buys of ACCO and WW. Price
targets are coming in the weekly Friday commentary.
Healthcare Innovators: Long-term subscribers of
this portfolio know how much Kevin likes medical devices company
Align Technology (ALGN). The portfolio has pulled profits from this
âsmile makerâ on several occasions, including a triple-digit return
last year. Now that shares have slipped 8% in the past week, the
editor canât resist adding this proven winner again. He also bought
GW Pharma (GWPH), which is the only FDA-approved cannabis drug
maker. Kevin thinks itâs headed to new highs above $200. Both ALGN
and GWPH are Zacks Rank #2s (Buys). The portfolio also sold the
stalling Illumina (ILMN), but still banked a nice return of
approximately 20% in 6 months. Read the full write-up for
more
Technology Innovators: The market is moving higher
and Brian would like to get this portfolio fully invested.
Therefore, he plans to add two positions this week. Todayâs buy was
Comtech Telecom (CMTL), a Zacks Rank #1 (Strong Buy) advanced
communications solutions company. The stock has a great earnings
history with an average positive surprise of 216% over the past
four quarters. Plus, CMTL is in the highly-ranked Wireless
Equipment space (top 7% of the Zacks Industry Rank) and enjoys a
good valuation. Read the full write-up for more and be prepared for
another buy on Thursday.
Zacks Short List: The portfolio swapped out two
names in this week's adjustment. It short-covered Boeing (BA) and
Inphi Corp. (IPHI), and immediately filled these spots by adding
salesforce.com (CRM) and CF Industries (CF). Learn more about this
emotion-free portfolio that takes advantage of falling and volatile
markets by reading the Short List Trader
Guide.
Until Tomorrow,
Jim Giaquinto
Recommendations from Zacks' Private
Portfolios:
Believe it or not, this article is not available on the Zacks.com
website. The commentary is a partial overview of the daily activity
from Zacks' private recommendation services. If you would like to
follow our Buy and Sell signals in real time, we've made a special
arrangement for readers of this website. Starting today you can see
all the recommendations from all of Zacks' portfolios absolutely
free for 7 days. Our services cover everything from value stocks
and momentum trades to insider buying and positive earnings
surprises (which we've predicted with an astonishing 80%+
accuracy). Click here to "test drive"
Zacks Ultimate for FREE >>
Zacks Investment Research